https://www.live-feeds.com/feed/the-heart-drug-pelacarsen-fails-shocking-novartis-and-cardiologistsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/the-heart-drug-pelacarsen-fails-shocking-novartis-and-cardiologistshttps://www.live-feeds.com/feed/the-heart-drug-pelacarsen-fails-shocking-novartis-and-cardiologists#u63088Wed, 09 Sep 2026 20:32:40 +0000Novartis experimental drug pelacarsen failed its Phase 3 Lp(a)HORIZON trial after failing to reduce strokes, heart attacks, or cardiovascular deaths. The drug successfully lowered the genetic cholesterol marker lipoprotein(a) by 80% in over 8,000 patients, but these biomarker reductions did not translate into clinical benefits. The results caused Novartis shares to drop 1.9%, erasing CHF4.9 billion in value, and triggered share price declines for Royalty Pharma, Amgen, and other rivals. Experts describe the result as a biomarker paradox that questions the efficacy of targeting Lp(a) after hear https://www.live-feeds.com/feed/the-heart-drug-pelacarsen-fails-shocking-novartis-and-cardiologistshttps://www.live-feeds.com/feed/the-heart-drug-pelacarsen-fails-shocking-novartis-and-cardiologists#u61141Tue, 08 Sep 2026 07:16:31 +0000Novartis shares fell 1.9 percent, erasing CHF4.9 billion after its experimental heart drug pelacarsen failed a late-stage trial. Although the therapy successfully lowered the targeted biomarker lipoprotein(a), it did not reduce deaths, heart attacks, or strokes. The failure missed the primary endpoint of the Lp(a)HORIZON study, shocking cardiologists and dealing a blow to expectations for this new cardiovascular treatment approach. Shares of related companies, including Amgen, also dropped following the disappointing results from the trial.Why it mattersThe failed late-stage trial evaluated th https://www.live-feeds.com/feed/the-heart-drug-pelacarsen-fails-shocking-novartis-and-cardiologistshttps://www.live-feeds.com/feed/the-heart-drug-pelacarsen-fails-shocking-novartis-and-cardiologists#u59977Mon, 07 Sep 2026 13:06:40 +0000Novartis and Ionis announced that their experimental cardiovascular drug pelacarsen failed to meet its primary endpoint in a late-stage clinical trial. The Phase III Lp(a)HORIZON study evaluated more than 8,000 patients with elevated lipoprotein levels to determine if the treatment could reduce the risk of major adverse cardiovascular events compared to a placebo. Instead of showing a reduction in heart attacks and strokes, the therapy missed its primary goal, shocking cardiologists and triggering stock selloffs for Novartis and related companies.Why it mattersPelacarsen was designed as a nove